Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
3Initial filing by director officer or owner of more than ten percent.Dec 21, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesDec 21, 2005View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventDec 19, 2005View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesDec 13, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesDec 6, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesDec 2, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesDec 2, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesDec 2, 2005View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventDec 2, 2005View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesNov 23, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesNov 23, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesNov 14, 2005View HTMLDownload DOCDownload PDF
10-QQuarterly report which provides a continuing view of a company's financial positionNov 3, 2005View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventNov 2, 2005View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesNov 1, 2005View HTMLDownload DOCDownload PDF
4/AAmendment to a previously filed 4Oct 17, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesOct 12, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesOct 6, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesOct 5, 2005View HTMLDownload DOCDownload PDF
POS AMPost-effective amendment to an S-Type filingSep 27, 2005View HTMLDownload DOCDownload PDFDownload XLS
POS AMPost-effective amendment to an S-Type filingSep 27, 2005View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GSep 8, 2005View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesSep 2, 2005View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventAug 24, 2005View HTMLDownload DOCDownload PDFDownload XLS
10-QQuarterly report which provides a continuing view of a company's financial positionAug 4, 2005View HTMLDownload DOCDownload PDFDownload XLS
1-25      26-50      51-75      76-100      101-107

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information